Alpelisib hydrochloride

Overview

Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα -selective inhibitor that blocks the conversion of PIP2 to PIP3 , thereby inhibiting pathways including PI3K/AKT/mTOR , MAPK/ERK , Notch and JAK-STAT . Alpelisib hydrochloride also induces apoptosis , G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin ( HY-13442 ) and exerts a synergistic effect with Paclitaxel ( HY-B0015 ), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer , gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Pain | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-15244A
• CAS No.: 1584128-91-5
• Molecular Formula: C19H23ClF3N5O2S
• Molecular Weight: 477.93
• Purity: 99.55%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 5 mg/mL (10.46 mM); Clear solution
• Availability: In-stock

Source

Original product source